Open Access<p>Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease</p>
Author(s) -
Lin Chen,
Xiujuan Zhang,
Li Zhang,
Donghai Zheng
Publication year - 2020
Publication title -
diabetes, metabolic syndrome and obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.853
H-Index - 43
ISSN - 1178-7007
DOI - 10.2147/dmso.s262284
Subject(s) - saxagliptin , medicine , fatty liver , endocrinology , dipeptidyl peptidase 4 inhibitor , lipotoxicity , steatosis , hyperinsulinemia , insulin resistance , dipeptidyl peptidase 4 , steatohepatitis , diabetes mellitus , type 2 diabetes , sitagliptin , disease
Non-alcoholic fatty liver disease (NAFLD) represents a broad spectrum of chronic liver disease characterized by aberrant accumulation of triglycerides (TG) in hepatocytes without excessive alcohol consumption. Hepatic lipotoxicity derived from overaccumulation of free fatty acids is considered as one of the typical hallmarks of NAFLD. Insulin resistance (IR) and chronic inflammation are widely recognized as the key etiological factors associated with NAFLD. Dipeptidyl peptidase 4 inhibitor (DPP4i) is a novel pharmacological agent extensively applied in the treatment of Type 2 Diabetes Mellitus (T2DM) for decades which also have a liver protective effect.